Esté J A, Witvrouw M, Tu J, Desmyter J, De Clercq E, Vandamme A M
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.
AIDS Res Hum Retroviruses. 1995 Nov;11(11):1355-8. doi: 10.1089/aid.1995.11.1355.
We have tested the effect of oncostatin M (OSM) on the Tat-mediated trans-activation in a HeLa cell line (HLtat) expressing Tat, using a transfection assay with the LacZ gene under the control of the HIV-1 LTR. Oncostatin M reduced the LacZ expression by 50% at a concentration of 9.5 ng/ml (IC50), which was far below the 50% cytotoxic concentration (CC50 > 400 ng/ml). Although HLtat cells may represent an interesting model for the study of the signal transduction pathway of OSM, this cytokine did not inhibit the tumor necrosis factor (TNF)-dependent activation of the HIV LTR in Molt pNAZ cells or the Tat-mediated trans-activation in HeLa, HeLa-CD4, Hep-II, COS-7, or Jurkat-tat cells. Likewise, OSM did not show any anti-HIV-1 activity in the MT4 cell/MTT assay. Our findings with OSM indicate that, for the screening of HIV Tat inhibitors, care must be taken in selecting a system that not only emulates HIV Tat trans-activation, but is also representative for in vivo-infected cells.
我们使用受HIV-1长末端重复序列(LTR)控制的LacZ基因转染试验,检测了抑瘤素M(OSM)对表达Tat的HeLa细胞系(HLtat)中Tat介导的反式激活作用的影响。抑瘤素M在浓度为9.5 ng/ml(IC50)时可使LacZ表达降低50%,该浓度远低于50%细胞毒性浓度(CC50>400 ng/ml)。尽管HLtat细胞可能是研究OSM信号转导途径的一个有趣模型,但这种细胞因子并未抑制Molt pNAZ细胞中肿瘤坏死因子(TNF)依赖的HIV LTR激活,也未抑制HeLa、HeLa-CD4、Hep-II、COS-7或Jurkat-tat细胞中Tat介导的反式激活。同样,在MT4细胞/MTT试验中,OSM未显示出任何抗HIV-1活性。我们对OSM的研究结果表明,在筛选HIV Tat抑制剂时,必须谨慎选择一个不仅能模拟HIV Tat反式激活,而且还能代表体内感染细胞的系统。